Chidamide suppresses macrophage-mediated immune evasion and tumor progression in small cell lung cancer by targeting the STAT4/CCL2 signaling pathway
Chidamide reshaped the SCLC TIME by activating STAT4/CCL2, thus driving M1 macrophage polarization and enhancing anti-tumor immunity. Our findings highlight coordinated TIME-targeted therapy as a translatable strategy to overcome therapeutic resistance in SCLC and provide a rationale for clinical trials examining epigenetic and anti-angiogenic therapeutics combinations.
Authors
- Ting Mei (ORCID: https://orcid.org/0000-0001-7756-040X)
- Tingting Qin (ORCID: https://orcid.org/0000-0002-1975-9696)
- Dingzhi Huang (ORCID: https://orcid.org/0000-0002-2798-9459)
- Yantao Jiang
- Wenting Liu (ORCID: https://orcid.org/0000-0002-8427-3414)
- Jingya Wang (ORCID: https://orcid.org/0000-0002-2527-6121)
- Mengjie Li (ORCID: https://orcid.org/0000-0002-0619-8754)
- Liuchun Wang
- Zhaoting Meng
Institutions
- Capital Medical University (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Beijing Friendship Hospital (CN)
Publication Details
- Journal
- Cancer Biology and Medicine
- Published
- 2025-10-23
- DOI
- https://doi.org/10.20892/j.issn.2095-3941.2024.0241
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00